Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

A Tanimoto, S Matsumoto, S Takeuchi, S Arai… - Clinical Cancer …, 2021 - AACR
Purpose: In ALK-rearranged non–small cell lung cancer (NSCLC), impacts of concomitant
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …
被引用次数：41 相关文章

[引用][C] Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

A Tanimoto, S Matsumoto, S Takeuchi, S Arai… - Clinical Cancer …, 2020 - cir.nii.ac.jp
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant
NSCLC via Noxa Expression | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.

A Tanimoto, S Matsumoto, S Takeuchi… - … Cancer Research: an …, 2020 - europepmc.org
Purpose In ALK-rearranged non-small cell lung cancer (NSCLC), impacts of concomitant
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

A Tanimoto, S Matsumoto… - … : an official journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose In ALK-rearranged non-small cell lung cancer (NSCLC), impacts of concomitant
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …
[PDF] researchgate.net

[PDF][PDF] Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa

A Tanimoto, S Matsumoto, S Takeuchi, S Arai… - Clin Cancer …, 2021 - researchgate.net
Purpose: In ALK-rearranged non–small cell lung cancer (NSCLC), impacts of concomitant
genetic alterations on targeted therapies with ALK-tyrosine kinase inhibitors (ALK-TKI) are …